Clinical trial
Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen
NCT00324610 · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie, Other · Unknown status
Key facts
| NCT number | NCT00324610 |
|---|---|
| Title | Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen |
| Official title | Phase I/II Study of Tolerance and Pharmacokinetics With Capecitabine Given 5 Days Out of 7 in Metastatic Breast Cancer |
| Lead sponsor | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Chemotherapy |
| Intervention type | Drug |
| Interventions | capecitabine |
| Enrollment | 46 |
| Start date | Mar 1, 2006 |
| First posted | May 11, 2006 |
| Last update posted | May 18, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: